Review of Current Policy Strategies to Reduce US Cancer Drug Costs.
作者信息
Green Angela K, Ohn Jennifer A, Bach Peter B
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
J Clin Oncol. 2020 Feb 1;38(4):372-379. doi: 10.1200/JCO.19.01628. Epub 2019 Dec 5.
Abstract
摘要
相似文献
1
Review of Current Policy Strategies to Reduce US Cancer Drug Costs.
J Clin Oncol. 2020 Feb 1;38(4):372-379. doi: 10.1200/JCO.19.01628. Epub 2019 Dec 5.
2
Overspending driven by oversized single dose vials of cancer drugs.
BMJ. 2016 Feb 29;352:i788. doi: 10.1136/bmj.i788.
3
Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
J Clin Oncol. 2007 Jun 20;25(18):2635-6; author reply 2637-8. doi: 10.1200/JCO.2007.11.4272.
4
Controlling the cost of innovative cancer therapeutics.
Nat Rev Clin Oncol. 2009 Sep;6(9):550-2. doi: 10.1038/nrclinonc.2009.113.
5
Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities.
Cancer. 2020 Aug 15;126(16):3613-3616. doi: 10.1002/cncr.32944. Epub 2020 May 21.
6
Can treatment costs be tamed?
Science. 2011 Mar 25;331(6024):1545-7. doi: 10.1126/science.331.6024.1545.
7
Tackling Cost: A Prescription for Spending Wisely.
J Natl Compr Canc Netw. 2019 Jun 1;17(6):633. doi: 10.6004/jnccn.2019.0030.
8
Value in Oncology: It Is in the Eyes of the Beholder.
J Natl Compr Canc Netw. 2019 Jan;17(1):2-5. doi: 10.6004/jnccn.2018.7092.
9
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Mayo Clin Proc. 2016 Jun;91(6):707-12. doi: 10.1016/j.mayocp.2016.04.028.
10
Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.
J Oncol Pract. 2014 Nov;10(6):357-62. doi: 10.1200/JOP.2014.001958.
引用本文的文献
1
Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.
Cancer Chemother Pharmacol. 2025 Feb 25;95(1):36. doi: 10.1007/s00280-025-04764-x.
2
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis.
EClinicalMedicine. 2024 Jun 20;73:102681. doi: 10.1016/j.eclinm.2024.102681. eCollection 2024 Jul.
3
Trends in Medicare utilization and reimbursement for hematology/oncology procedures from 2012 to 2023: A geriatric oncology perspective.
Aging Med (Milton). 2024 Apr 9;7(2):171-178. doi: 10.1002/agm2.12298. eCollection 2024 Apr.
4
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
JMIR Cancer. 2024 Apr 4;10:e54178. doi: 10.2196/54178.
5
Trends in brand and generic drug utilization for dermatology providers from 2013-2019.
Arch Dermatol Res. 2023 May;315(4):1041-1044. doi: 10.1007/s00403-022-02431-2. Epub 2022 Oct 30.
6
Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform.
Gynecol Oncol. 2022 Jul;166(1):162-164. doi: 10.1016/j.ygyno.2022.05.008. Epub 2022 May 18.
7
The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis.
Cancers (Basel). 2021 Nov 27;13(23):5977. doi: 10.3390/cancers13235977.
8
Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: A systematic review.
Mol Oncol. 2021 Oct;15(10):2672-2687. doi: 10.1002/1878-0261.13038. Epub 2021 Jul 19.
9
Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question.
Clin Transl Oncol. 2021 Aug;23(8):1511-1519. doi: 10.1007/s12094-021-02563-3. Epub 2021 Feb 13.
10
Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Am J Obstet Gynecol. 2021 Jul;225(1):68.e1-68.e11. doi: 10.1016/j.ajog.2021.01.029. Epub 2021 Feb 4.
本文引用的文献
1
Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review.
JAMA Oncol. 2019 Jun 1;5(6):893-899. doi: 10.1001/jamaoncol.2018.6196.
2
3
Expansion of the Medicare 340B Payment Program: Hospital Participation, Prescribing Patterns and Reimbursement, and Legal Challenges.
JAMA. 2018 Dec 11;320(22):2311-2312. doi: 10.1001/jama.2018.15667.
4
Going for Broke: A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care.
J Oncol Pract. 2018 Sep;14(9):e533-e546. doi: 10.1200/JOP.18.00112. Epub 2018 Aug 23.
5
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.
Rand Health Q. 2018 Mar 30;7(4):3. eCollection 2018 Mar.
6
Value-Based Pricing for Drugs: Theme and Variations.
JAMA. 2018 Jun 5;319(21):2165-2166. doi: 10.1001/jama.2018.4871.
7
Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Am J Manag Care. 2017 Mar;23(3 Suppl):S39-S45.
8
FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
JAMA. 2017 Nov 21;318(19):1861-1862. doi: 10.1001/jama.2017.15218.
9
Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
JAMA Intern Med. 2017 Aug 1;177(8):1185-1188. doi: 10.1001/jamainternmed.2017.1885.
10
Pricing in the Market for Anticancer Drugs.
J Econ Perspect. 2015;29(1):139-62. doi: 10.1257/jep.29.1.139.
Zotero 插件